Related Experiment Videos
Experimental Charcot-Marie-Tooth type 1A: a cDNA microarrays analysis
Tiziana Vigo1, Lucilla Nobbio, Paul Van Hummelen
1Department of Neurosciences, Ophthalmology and Genetics, University of Genova, Italy, via De Toni 5, 16132 Genova, Italy.
Molecular and Cellular Neurosciences
|March 31, 2005
Summary
Overexpression of the peripheral myelin protein 22 (PMP22) gene in Charcot-Marie-Tooth neuropathy type 1A (CMT1A) down-regulates gene expression, including ciliary neurotrophic factor (CNTF). This reduction in CNTF may impair Schwann cell support, contributing to axonal atrophy.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Charcot-Marie-Tooth neuropathy type 1A (CMT1A) is a genetic disorder caused by the overexpression of the peripheral myelin protein 22 (PMP22) gene.
- Understanding the molecular mechanisms underlying CMT1A is crucial for developing effective treatments.
Purpose of the Study:
- To identify genes modulated by PMP22 overexpression in CMT1A.
- To investigate the impact of PMP22 on ciliary neurotrophic factor (CNTF) expression and its role in the disease pathogenesis.
Main Methods:
- cDNA microarray analysis of sciatic nerves from a rat model of CMT1A.
- Real-time PCR and ELISA to quantify CNTF mRNA and protein levels.
- Analysis of human CMT1A sural nerve biopsies and primary cultures of transgenic Schwann cells.
Main Results:
- PMP22 overexpression led to significant down-regulation of 86 genes and up-regulation of 23 genes in peripheral nerve tissue.
- Selective down-regulation of CNTF transcript, cell cycle regulators, cytoskeletal proteins, and extracellular matrix proteins was observed.
- CNTF mRNA and protein levels were reduced in transgenic sciatic nerves, human CMT1A biopsies, and transgenic Schwann cells.
Conclusions:
- PMP22 overexpression in CMT1A induces a general down-regulation of gene expression in peripheral nerves.
- Reduced CNTF expression in CMT1A Schwann cells suggests impaired trophic support to axons, potentially contributing to axonal atrophy.
- These findings elucidate PMP22's molecular function and CMT1A's pathogenic mechanisms.